These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 14611676)

  • 1. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma.
    Sawada M; Tsuda H; Kimura M; Okamoto S; Kita T; Kasamatsu T; Yamada T; Kikuchi Y; Honjo H; Matsubara O
    Cancer Sci; 2003 Nov; 94(11):986-91. PubMed ID: 14611676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
    Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
    Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate.
    Wang X; Jones TD; Zhang S; Eble JN; Bostwick DG; Qian J; Lopez-Beltran A; Montironi R; Harris JJ; Cheng L
    Mod Pathol; 2007 Feb; 20(2):175-82. PubMed ID: 17192792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma.
    Semiz HS; Pala EE; Can B; Atag E; Gungor H; Sanci M
    Turk Patoloji Derg; 2023; 39(1):55-63. PubMed ID: 36178283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation.
    Tsuda H; Morita D; Kimura M; Shinto E; Ohtsuka Y; Matsubara O; Inazawa J; Tamaki K; Mochizuki H; Tamai S; Hiraide H
    Cancer Sci; 2005 Jan; 96(1):48-53. PubMed ID: 15649255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERBB-2 gene overexpression and amplification in uterine sarcomas.
    Amant F; Vloeberghs V; Woestenborghs H; Debiec-Rychter M; Verbist L; Moerman P; Vergote I
    Gynecol Oncol; 2004 Dec; 95(3):583-7. PubMed ID: 15581967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma.
    Saglam O; Husain S; Toruner G
    Int J Gynecol Pathol; 2013 Sep; 32(5):493-500. PubMed ID: 23896716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach.
    Murakawa T; Tsuda H; Tanimoto T; Tanabe T; Kitahara S; Matsubara O
    Pathol Int; 2005 Dec; 55(12):757-65. PubMed ID: 16287490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy.
    Raspollini MR; Mecacci F; Paglierani M; Marchionni M; Taddei GL
    Pathol Res Pract; 2005; 201(2):141-4. PubMed ID: 15901136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with 'stem-cell-like' features.
    Tsuda H; Tani Y; Weisenberger J; Kitada S; Hasegawa T; Murata T; Tamai S; Hirohashi S; Matsubara O; Natori T
    Cancer Sci; 2005 Jun; 96(6):333-9. PubMed ID: 15958055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of receptor tyrosine kinases in esophageal carcinosarcoma.
    Sano A; Sakurai S; Kato H; Suzuki S; Yokobori T; Sakai M; Tanaka N; Inose T; Sohda M; Nakajima M; Fukai Y; Miyazaki T; Ojima H; Hosoya Y; Enomoto T; Kanda T; Ajioka Y; Kuwano H
    Oncol Rep; 2013 Jun; 29(6):2119-26. PubMed ID: 23546020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
    Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
    Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
    Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
    Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.
    Gilbert JA; Goetz MP; Reynolds CA; Ingle JN; Giordano KF; Suman VJ; Blair HE; Jenkins RB; Lingle WL; Reinholz MM; Adjei AA; Ames MM
    Mol Cancer Ther; 2008 Apr; 7(4):944-51. PubMed ID: 18413808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?
    Raspollini MR; Susini T; Amunni G; Paglierani M; Castiglione F; Garbini F; Carriero C; Scarselli G; Taddei GL
    Int J Gynecol Cancer; 2006; 16(1):416-22. PubMed ID: 16445668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogene alterations in endometrial carcinosarcomas.
    Biscuola M; Van de Vijver K; Castilla MÁ; Romero-Pérez L; López-García MÁ; Díaz-Martín J; Matias-Guiu X; Oliva E; Palacios Calvo J
    Hum Pathol; 2013 May; 44(5):852-9. PubMed ID: 23199529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.
    Williams MD; Roberts DB; Kies MS; Mao L; Weber RS; El-Naggar AK
    Clin Cancer Res; 2010 Apr; 16(8):2266-74. PubMed ID: 20371674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization.
    Odicino FE; Bignotti E; Rossi E; Pasinetti B; Tassi RA; Donzelli C; Falchetti M; Fontana P; Grigolato PG; Pecorelli S
    Int J Gynecol Cancer; 2008; 18(1):14-21. PubMed ID: 17451461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization.
    Wang X; MacLennan GT; Zhang S; Montironi R; Lopez-Beltran A; Tan PH; Foster S; Baldridge LA; Cheng L
    Hum Pathol; 2009 Feb; 40(2):211-7. PubMed ID: 18799188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.
    Bhargava R; Gerald WL; Li AR; Pan Q; Lal P; Ladanyi M; Chen B
    Mod Pathol; 2005 Aug; 18(8):1027-33. PubMed ID: 15920544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.